Cocrystal Pharma, Inc.
COCP
$1.49
-$0.06-3.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.36M | 2.04M | 3.24M | 4.31M | 2.95M |
| Gross Profit | -1.36M | -2.04M | -3.24M | -4.31M | -2.95M |
| SG&A Expenses | 981.00K | 1.19M | 1.80M | 1.14M | 1.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.34M | 3.23M | 5.04M | 5.45M | 4.16M |
| Operating Income | -2.34M | -3.23M | -5.04M | -5.45M | -4.16M |
| Income Before Tax | -2.30M | -3.27M | -4.94M | -5.34M | -3.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.30M | -3.27M | -4.94M | -5.34M | -3.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.30M | -3.27M | -4.94M | -5.34M | -3.96M |
| EBIT | -2.34M | -3.23M | -5.04M | -5.45M | -4.16M |
| EBITDA | -2.32M | -3.20M | -5.01M | -5.42M | -4.12M |
| EPS Basic | -0.23 | -0.32 | -0.49 | -0.53 | -0.39 |
| Normalized Basic EPS | -0.14 | -0.20 | -0.30 | -0.33 | -0.24 |
| EPS Diluted | -0.23 | -0.32 | -0.49 | -0.53 | -0.39 |
| Normalized Diluted EPS | -0.14 | -0.20 | -0.30 | -0.33 | -0.24 |
| Average Basic Shares Outstanding | 10.17M | 10.17M | 10.17M | 10.17M | 10.17M |
| Average Diluted Shares Outstanding | 10.17M | 10.17M | 10.17M | 10.17M | 10.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |